#Sweden #Stockholm #Annual Report #Sobi #Rare Diseases

Sobi's Annual and Sustainability Report for 2025

On March 31, 2026, Swedish Orphan Biovitrum AB, commonly known as Sobi®, announced the publication of its Annual and Sustainability Report for 2025. This document encapsulates the extensive progress the company has made in developing innovative therapies aimed at treating individuals afflicted with rare diseases.

Focus on Rare Diseases

Sobi has strategically concentrated its efforts on addressing the unique challenges faced by patients with rare disorders. In line with this commitment, the report reveals that over 53,000 full-time equivalent patients benefitted from Sobi's medicines in 2025. This achievement underscores the company's dedication to ensuring universal access to its treatments across therapeutic areas.

In a significant financial highlight, Sobi reported a 15 percent increase in revenue, reaching a remarkable SEK 28 billion in 2025 at constant exchange rates (CER). The growth in revenue is indicative of Sobi's successful development pipeline, which has been engineered to redefine standard care practices in various severe rare diseases, demonstrating the company's substantial impact on patient lives.

Commitment to Sustainability

The 2025 report is noteworthy not only for its financial data but also for its deep commitment to sustainability. Sobi is aligning its reporting with the Swedish Annual Accounts Act and the European Reporting Standards (ESRS), thus ensuring that its sustainability practices meet the current regulatory framework. Furthermore, the report integrates the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) and adheres to the EU Taxonomy reporting requirements, reflecting Sobi's proactive stance on environmental stewardship.

Sobi’s Sustainability Statement delineates the organization's transition to the Corporate Sustainability Reporting Directive (CSRD), ensuring that its sustainability narrative is both impactful and comprehensive. By aligning the structure and content of the report with emerging sustainability requirements, Sobi reinforces its commitment to transparency and accountability in its operations.

Availability and Accessibility

The comprehensive 2025 Annual and Sustainability Report is accessible to the public on Sobi's official website, sobi.com. In addition, the Swedish version of the report is provided in the European Single Electronic Format (ESEF), ensuring that it meets the accessibility standards expected in Europe. In cases of discrepancies or inquiries, the ESEF version will serve as the authoritative reference.

Sobi, with a global workforce of approximately 1,900 employees across various regions including Europe, North America, the Middle East, Asia, and Australia, continues to forge ahead in its mission to unlock breakthrough innovations. The operational framework focuses on not merely exceptional economic performance, but also on a solution-oriented approach to the needs of patients with rare diseases.

In light of these achievements, Sobi's stock (STO: SOBI) retains its position on Nasdaq Stockholm. The company remains dedicated to pushing the boundaries of medical advancements while also championing sustainable business practices aimed at improving the quality of life for patients living with rare conditions. Such initiatives highlight the importance of collaboration, scientific expertise, and a patient-centered focus in the evolving landscape of biopharmaceuticals.

Conclusion

Sobi's Annual and Sustainability Report for 2025 is more than an account of financial results; it illustrates the ongoing journey of a biopharma leader committed to transforming the landscape of treatment for rare diseases. As they push forward, the consistent integration of sustainability in their operational blueprint ensures that Sobi not only invests in tomorrow's innovations but also secures a healthy planet for future generations.

For further details regarding Sobi, their advancements, or investor relations, you may contact Gerard Tobin, Head of Investor Relations, or visit their media contact page online.

In conclusion, Sobi's comprehensive approach to both innovation and sustainability in 2025 stands as a testament to their commitment to bettering the lives of those living with rare diseases while also ensuring the health of the planet.